Less Ads, More Data, More Tools Register for FREE

MaxCyte inks deal with South Korea's Curamys

Mon, 05th Dec 2022 13:28

(Sharecast News) - Cell engineering technology company MaxCyte announced a strategic platform licence with South Korea-based biotechnology specialist Curamys on Monday, which develops cell and gene therapies using cell fusion technology to treat rare intractable diseases, including Duchenne muscular dystrophy and amyotrophic lateral sclerosis.

The AIM-traded firm said that under the deal, Curamys would obtain non-exclusive clinical and commercial rights to use MaxCyte's 'Flow Electroporation' technology and 'ExPERT' platform.

In return, MaxCyte would receive platform licensing fees and programme-related revenue.

The board said Curamys is focussed on developing treatments for genetic and degenerative diseases through its specialised cell fusion technology, based on the concept that apoptotic or dying cells could be regenerated by fusing them with healthy, "normal" cells.

Cell fusion technology can function as a form of gene therapy when the normal copies of genes existing in treatment cells are transferred to dying cells, resulting in the development of treatments for genetic and rare intractable diseases at the cellular level.

"A recent report estimates that there are more than 10,000 distinct rare diseases affecting 400 million people around the world," said president and chief executive officer Doug Doerfler.

"Many of these diseases, like ALS and DMD, have few or no treatments.

"We are honoured to support Curamys' efforts to develop its cell-fusion technology for novel cell-based treatments that provide hope and new options to patients and their families."

At 1222 GMT, shares in MaxCyte were up 1.63% in London, at 500p.

Reporting by Josh White for Sharecast.com.

Related Shares

More News
30 Jan 2024 13:58

IN BRIEF: MaxCyte signs licencing deal with cell therapy company Wugen

MaxCyte Inc - Maryland, US-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Signs strategic p...

29 Jan 2024 17:56

IN BRIEF: MaxCyte chief scientific officer leaves firm

MaxCyte Inc - Maryland, US-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Announces departu...

23 Jan 2024 18:39

TRADING UPDATES: Esken's Southend Airport faces further allegations

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

9 Jan 2024 12:18

MaxCyte's strategic platform licences redeem otherwise modest results

(Alliance News) - MaxCyte Inc on Tuesday said that promising returns from its strategic platform licence program had bolstered its quarterly revenue e...

9 Jan 2024 08:55

MaxCyte flags uptick in total fourth-quarter revenue

(Sharecast News) - Cell engineering company MaxCyte said on Tuesday that total fourth-quarter revenue was expected to be between $15.5m and $15.7m.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.